symp1

0

A. Rousseau (France): Adaptive control methods for the dose individualisation of anticancer agents.

A.V. Boddy (U.K.): Rationale for the TDM of anticancer drugs.

E. Chatelut (France): Clinical application of the population modelling of platinum compounds.

B. Lemmer (Germany): Chronopharmacokinetics of anticancer drugs: are they clinically relevant?

S.P. Joel (U.K.): Pharmacology and therapeutic monitoring of continuous infusion of etoposide in small-cell lung cancer.